Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Creo Medical ( (GB:CREO) ) just unveiled an announcement.
Creo Medical Group plc has published its 2024 Annual Report and Accounts along with the Notice of its Annual General Meeting (AGM) on its website. The AGM is scheduled for 26 June 2025, where shareholders are encouraged to vote by proxy due to potential unforeseen circumstances. This announcement underscores the company’s commitment to transparency and shareholder engagement, while also highlighting its strategic focus on minimally invasive surgical endoscopy for cancer patients.
More about Creo Medical
Creo Medical Group plc is a medical device company specializing in the development and commercialization of minimally invasive electrosurgical devices. The company focuses on improving patient outcomes through its advanced energy technology, CROMA powered by Kamaptive, which enhances surgical capabilities and patient outcomes by integrating multi-modal energy sources for procedures such as resection, dissection, coagulation, and ablation.
Average Trading Volume: 1,703,705
Technical Sentiment Signal: Sell
Current Market Cap: £56.72M
Learn more about CREO stock on TipRanks’ Stock Analysis page.